The combination of greater longevity and some bad lifestyle choices in the developed world are resulting in an increasing incidence of a wide range of chronic ailments including diabetes, cancer and neuro-degenerative diseases. This results in a growing demand for drugs as well as presenting new targets for drug development. Yet despite this positive market outlook the global pharma industry is facing an existential crisis. The causes/symptoms of this crisis have been well-rehearsed: expiration of patents for blockbuster drugs, escalating development costs and shrinking development pipeline; these factors are exacerbated by governmental pressure to reduce expenditure on public drug purchase schemes.
This session will explore how to rekindle innovation in the pharma industry and in particular how Europe can take the lead in getting the industry on a viable path?Specific questions to be addressed include:
Attendance numbers do not account for private attendees. Get there early!